The category of therapeutic bioproducts not only includes antibodies, recombinant proteins and vaccines but also gene therapy, somatic cell therapy and tissue engineered products. The market of these innovative products is predicted to continue to grow 10% per year leading to a continuous increase of the demand of highly specialized CMOs for the production of investigational biopharmaceutical drugs for clinical trials.

Among the drug candidates, more than 60% will be employed in the fields of oncology, infectious diseases, central nervous system and inflammatory diseases.

The saturation of the worldwide production capacity together with the high dosages and prolonged therapies will cause the biotech companies to outsource the development, scale-up and manufacturing of biopharmaceuticals.

In the recent years, areta emerged as a company dedicated to the preclinical development and cGMP manufacturing of innovative biological drugs and advanced therapy medicinal products.